Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- CVCO +2.5%, SOI +1.5%
M&A news:
- CLNT +24.8% (Cleantech Solutions enters into exclusive discussions with ECrent Capital Holdings Limited)
Select tech names showing strength in pre-mkt following recent sell-off:
- NVDA +2.5%, JD +1.5%, NFLX +1.5%, MU +1.5%, MOMO +1.4%, AMAT +1.4%, AAPL +1%
Other news:
- ABIL +27.4% (continued volatility in pre-mkt)
- MNGA +22.3% (awarded a $431,874 grant from the USDA)
- PSDV +7.2% (announces that the second Phase 3 trial of Durasert three-year treatment for posterior segment uveitis achieved the trial's primary endpoint)
- SYNA +6.8% (Synaptics to acquire voice and audio processing solutions company Conexant Systems and Multimedia Solutions Business from Marvell (MRVL); updates guidance)
- CHRS +6.2% (Coherus BioSciences confirms that on June 9, the Patent Trial and Appeal Board ruled in favor of the Company's petitions for Inter Partes Review of AbbVie's (ABBV) U.S. 9,017,680 and 9,073,987)
- BCLI +4.9% (receives grant from Israel Innovation Authority for $2.1 mln)
- CAMT +3.8% (modestly rebounding following multiple day declines)
- AHH +3.5% ( will replace Pinnacle Financial Partners in the S&P SmallCap 600)
- CGIX +2.6% (10% owner/Director disclosed purchase of 100K shares worth total of $375K)
- IMAX +1.3% (authorizes new $200 mln share-repurchase program and cost-reduction initiative )
- DVAX +1.3% (continued strength)
- ADMS +1.1% (Adamas Pharmaceuticals announces that results of its Phase 3 EASE LID clinical trial of ADS-5102 were published online in JAMA Neurology; placebo-controlled phase 3 trial demonstrated that ads-5102 significantly reduced both dyskinesia and off time at six months in parkinson's disease patients with levodopa-induced dyskinesia)
- NVO +0.9% (reports new data for Victoza indicating reduction of cardiovascular risk in people with type 2 diabetes)
Analyst comments:
- CLVS +4% (initiated with a Outperform at Leerink Partners)
- DATA +3% (upgraded to Buy from Neutral at Goldman )
- LUX +3% (upgraded to Overweight from Equal Weight at Morgan Stanley)
- GLOG +2.4% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- TSLA +2.1% (upgraded to Buy from Hold at Berenberg )